Skip to content

BURZYNSKI RESEARCH INSTITUTE INC: 10-Q filed 2026-01-13

What BURZYNSKI RESEARCH INSTITUTE INC reported in its quarterly report filed 2026-01-13 (fiscal Q3 2026): 26 published measures, 85 facts as tagged in accession 0001104659-26-003337.

This filing

Form
10-Q (quarterly report)
Filed
2026-01-13
Fiscal period
fiscal Q3 2026
Accession
0001104659-26-003337 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BURZYNSKI RESEARCH INSTITUTE INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-11-302,265USD
At 2025-02-28847USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-11-3069,608USD
At 2025-02-2842,484USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-11-30-67,343USD
At 2025-08-31-69,571USD
At 2025-05-31-69,716USD
At 2025-02-28-41,637USD
At 2024-11-30-21,326USD
At 2024-08-31-87,634USD
At 2024-05-31-127,868USD
At 2024-02-29-25,123USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-11-302,165USD
At 2025-02-28847USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-328,862USD91
2025-03-01 to 2025-11-30-994,180USD275
2025-06-01 to 2025-08-31-333,867USD92
2025-03-01 to 2025-05-31-331,451USD92
2024-09-01 to 2024-11-30-352,239USD91
2024-03-01 to 2024-11-30-1,093,409USD275
2024-06-01 to 2024-08-31-369,838USD92
2024-03-01 to 2024-05-31-371,332USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-03-01 to 2025-11-30-967,156USD275
2024-03-01 to 2024-11-30-1,097,903USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-03-01 to 2025-11-30968,474USD275
2024-03-01 to 2024-11-301,097,206USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-11-30-130,470,593USD
At 2025-02-28-129,476,413USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-09-01 to 2025-11-30131,448,444shares91
2025-03-01 to 2025-11-30131,448,444shares275
2024-09-01 to 2024-11-30131,448,444shares91
2024-03-01 to 2024-11-30131,448,444shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-09-01 to 2025-11-30131,448,444shares91
2025-03-01 to 2025-11-30131,448,444shares275
2024-09-01 to 2024-11-30131,448,444shares91
2024-03-01 to 2024-11-30131,448,444shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-09-01 to 2025-11-300USD/shares91
2025-03-01 to 2025-11-30-0.01USD/shares275
2024-09-01 to 2024-11-300USD/shares91
2024-03-01 to 2024-11-30-0.01USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-09-01 to 2025-11-300USD/shares91
2025-03-01 to 2025-11-30-0.01USD/shares275
2024-09-01 to 2024-11-300USD/shares91
2024-03-01 to 2024-11-30-0.01USD/shares275

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-09-01 to 2025-11-300USD91
2025-03-01 to 2025-11-300USD275
2024-09-01 to 2024-11-300USD91
2024-03-01 to 2024-11-300USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-328,862USD91
2025-03-01 to 2025-11-30-994,180USD275
2024-09-01 to 2024-11-30-352,239USD91
2024-03-01 to 2024-11-30-1,093,409USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-11-302,265USD
At 2025-02-28847USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-11-3045,101USD
At 2025-02-2817,017USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-09-01 to 2025-11-30328,862USD91
2025-03-01 to 2025-11-30994,180USD275
2024-09-01 to 2024-11-30352,239USD91
2024-03-01 to 2024-11-301,093,409USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-09-01 to 2025-11-30260,800USD91
2025-03-01 to 2025-11-30786,189USD275
2024-09-01 to 2024-11-30301,183USD91
2024-03-01 to 2024-11-30804,447USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-11-30131,448,444shares
At 2025-02-28131,448,444shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-11-302,165USD
At 2025-02-28847USD
At 2024-11-30613USD
At 2024-02-291,310USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-11-3024,507USD
At 2025-02-2825,467USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2025-11-300USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-328,862USD91
2025-03-01 to 2025-11-30-994,180USD275
2024-09-01 to 2024-11-30-352,239USD91
2024-03-01 to 2024-11-30-1,093,409USD275

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-03-01 to 2025-11-30-994,180USD275
2024-03-01 to 2024-11-30-1,093,409USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-09-01 to 2025-11-3068,062USD91
2025-03-01 to 2025-11-30207,991USD275
2024-09-01 to 2024-11-3051,056USD91
2024-03-01 to 2024-11-30288,962USD275

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-03-01 to 2025-11-3028,084USD275
2024-03-01 to 2024-11-308,771USD275

Inspect the source

Entity
BURZYNSKI RESEARCH INSTITUTE INC / CIK 0000724445
Captured
2026-09-19T15:00:09.958Z
SEC response SHA-256
280fe93908eb6d3bca8df7351a6ce86b0d12e15fb5a41d56bd44784f717cff04

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000724445.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))